Physician profile
Deborah Giambanco
NPI 1962679316
$2,227.19
in general payments reported to CMS, 2019-2025
14 companies · $224 in 2025
The $224 reported for 2025 was more than what 90% of Neonatal, Critical Care providers received nationally (typical 2025 total: $45.50).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.42 · 2022: $48.77 · 2023: $1,616 · 2024: $247 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236 · Travel and Lodging: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.70 |
| Travel and Lodging | $851.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,432.26 | 2023 | Neurostar Tms Therapy System |
| Abbvie INC. | $280.98 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $129.28 | 2021-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $117.62 | 2023-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $61.06 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $35.89 | 2024 | Trintellix |
| Axsome Therapeutics, INC. | $35.86 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $32.07 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $20.27 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.49 | 2025 | Caplyta |
| Tempus Ai, INC | $18.93 | 2024 | |
| Vertical Pharmaceuticals, LLC | $17.88 | 2024 | Relexxii |
| Corium, LLC | $13.60 | 2025 | Azstarys |
| Allergan, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Giambanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.